Case report

Nonbacterial thrombotic endocarditis with embolic cerebral vascular accidents in a patient with advanced, recurrent clear cell carcinoma of the ovary: A case report

Lusha W. Liang a,1, Alexander R. Perez a,1, Nicholas A. Cangemi b, Robert J. Young c, Vicky Makker b,d,*

a Weill Cornell Medical Center, 1300 York Ave, New York, NY 10065, United States
b Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, United States
c Department of Neuroradiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
d Department of Medicine, Weill Cornell Medical Center, 1300 York Ave, New York, NY 10065, United States

Article history:
Received 28 August 2015
Received in revised form 11 March 2016
Accepted 15 March 2016
Available online 17 March 2016

Keywords:
Nonbacterial thrombotic endocarditis
Valvular vegetations
Embolic stroke
Ovarian clear cell carcinoma
Ovarian cancer
Anticoagulation

1. Introduction

Nonbacterial thrombotic endocarditis (NBTE) is characterized by deposition of sterile platelet and fibrin thrombi on valvular structures, which are prone to embolism and most commonly involve the cerebrovascular circulation (González et al., 1991; Sørensen et al., 2000). NBTE is not uncommon in patients with advanced mucin-secreting ovarian adenocarcinomas, and a few case reports have shown an association with ovarian clear cell cancer (OCCC) (Heit et al., 2000; Aryana et al., 2006; Devulapalli et al., 2012; Naoi et al., 2013). In North America and Europe, OCCC is the second most common histologic subtype of epithelial ovarian cancer, with an estimated prevalence of 1–12% (Goff et al., 1996). Advanced OCCC carries a poor prognosis and is associated with an elevated risk of vascular thrombotic events, with as many as 40% of patients experiencing thromboembolic events (Goff et al., 1996). Here we report on a patient with metastatic OCCC presenting with embolic cerebrovascular accidents (CVAs) while on treatment for recurrent disease.

2. Case

A 68-year-old Caucasian female developed shortness of breath in May 2010. Computed tomography (CT) of the chest, abdomen and pelvis revealed a pulmonary embolus (PE) in the right lower lobe pulmonary artery, a 16.6 × 13.1 cm pelvic mass, retroperitoneal lymphadenopathy, right pleural effusion, and a right pleural-based mass measuring 1.8 × 1.3 cm. CA-125 tumor marker was elevated at 358 U/mL. The patient was placed on dalteparin for PE management.

One month later she underwent exploratory laparotomy with total abdominal hysterectomy, bilateral salpingo-oophorectomy, bilateral ureterolysis, para-aortic lymph node dissection, ablation of diaphragmatic nodules, and liver right lobe wedge resection. Pathology revealed stage IVB OCCC. Of note, the patient underwent prophylactic inferior vena cava filter placement preoperatively and was started on enoxaparin following complete gross surgical debulking.

Following surgery, the patient enrolled in Gynecologic Oncology Group (GOG) 252, a phase III trial of bevacizumab with intravenous (IV) versus intraperitoneal (IP) chemotherapy, and received six cycles of IP carboplatin at an area under the curve (AUC) of 6 on day 1 and weekly IV paclitaxel 80 mg/m² on days 1, 8, and 15. With the start of cycle 2 she also received IV bevacizumab at 15 mg/kg once every 3 weeks. After the last dose of combination chemotherapy, the patient was maintained on IV bevacizumab at 15 mg/kg once every 3 weeks for a total of 16 additional cycles, which she completed in 12/2011. One month after completion of maintenance bevacizumab therapy, CT revealed progression of disease in liver segment 4B and the right pleura. The patient underwent a video-assisted thoracoscopic surgery (VATS), thoracic lymphadenectomy, open celiac lymphadenectomy, and partial hepatectomy. Postoperatively, it was recommended that she restarts enoxaparin, but she elected to forego further anticoagulation therapy. Following secondary debulking, the patient was treated with weekly paclitaxel and investigational VTX-2337 from 8/2012 to 11/2012, followed by carboplatin and liposomal doxorubicin from 11/12 to 2/13, and gemcitabine and bevacizumab in 3/13, but her disease continued to progress.
In April 2013, 6 weeks after her last dose of bevacizumab, the patient presented with a 3-day history of headaches and sudden onset visual changes. She described “blobs” in her visual field and impairment in her peripheral vision. Within hours, she developed confusion, with the inability to remember any events of the prior 24 h. Neurological exam revealed a left homonymous hemianopsia and retrograde short-term memory loss. She was afibrile and her vital signs revealed: pulse 96, blood pressure 139/56, respiratory rate 20, and oxygen saturation 96, 9. blood urea nitrogen; PT, prothrombin time; PTT, partial thromboplastin time; INR, international normalized ratio; ESR, erythrocyte sedimentation rate; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.

Non-contrast CT of the brain revealed an area of low attenuation without gadolinium revealed acute infarcts in the right greater than left occipital lobes, parietal lobes, posterior corpus callosum, and posterior mesial temporal lobes. The patient’s vision and memory improved gradually, but never returned to baseline. A cardiac MRI revealed normal left ventricular size and an EF of 69%. Follow-up TTE revealed an EF of 65% and thickened mitral valve leaflets that opened well.

In April 2013, 6 weeks after her last dose of bevacizumab, the patient presented with a 3-day history of headaches and sudden onset visual changes. She described “blobs” in her visual field and impairment in her peripheral vision. Within hours, she developed confusion, with the inability to remember any events of the prior 24 h. Neurological exam revealed a left homonymous hemianopsia and retrograde short-term memory loss. She was afibrile and her vital signs revealed: pulse 96, blood pressure 139/56, respiratory rate 20, and oxygen saturation 96, blood pressure 139/56, respiratory rate 20, and oxygen saturation 96, 9. blood urea nitrogen; PT, prothrombin time; PTT, partial thromboplastin time; INR, international normalized ratio; ESR, erythrocyte sedimentation rate; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.

Non-contrast CT of the brain revealed an area of low attenuation without gadolinium revealed acute infarcts in the right greater than left occipital lobes, parietal lobes, posterior corpus callosum, and posterior mesial temporal lobes. The patient’s vision and memory improved gradually, but never returned to baseline. A cardiac MRI revealed normal left ventricular size and an EF of 69%. Follow-up TTE revealed an EF of 65% and thickened mitral valve leaflets that opened well.

Repeat brain MRI 2 weeks after initial presentation revealed evolving subacute infarcts in the right greater than left occipital lobes, parietal lobes, posterior corpus callosum, and posterior mesial temporal lobes. The patient’s vision and memory improved gradually, but never returned to baseline. A cardiac MRI revealed normal left ventricular size and an EF of 69%. Follow-up TTE revealed an EF of 65% and thickened mitral valve leaflets that opened well.

The patient re-initiated systemic therapy for advanced OCCC with pemetrexed and bevacizumab followed by irinotecan and bevacizumab, but unfortunately, her OCCC continued to progress. While on palliative therapy for progressive disease, the patient remained on enoxaparin and did not experience further embolic neurologic complications. The patient died from end-stage OCCC 7 months following her NBTE diagnosis.

### 3. Discussion

Thrombosis constitutes the most frequent complication and second most common cause of death in cancer patients, with the emergence of thromboembolic disease occasionally preempts the diagnosis of malignancy, as first noted by Trousseau in 1865 (Zacharski et al., 1983; Rickles & Edwards, 1983). Malignancy promotes a prothrombotic state in patients via aberrant production of tissue factor and cancer procoagulant, such as interleukin 1β (IL-1β), tumor necrosis factor alpha (TNF-α), and vascular endothelial growth factor (VEGF) (Dranoff, 2004). TNF-α and IL-1β derived from malignant cells can induce endothelial cells to increase tissue factor procoagulant activity and to produce the fibrinolysis inhibitor plasminogen activator inhibitor 1. This accelerates the prothrombotic potential of endothelial cells in malignancy. (Lee & Levine, 1999).

It is the hypercoagulable state of malignancy that is thought to permit NBTE, (Aryana et al., 2006) a non-infectious endocarditis characterized by thrombi composed of immune complexes, mononuclear cells, and fibrin. NBTE more commonly involves the mitral (64%) and aortic (25%) valves (Steiner, 1993), and is a complication that is mainly but not exclusively associated with advanced malignancy. In a prospective study of 200 cancer patients, echocardiographic evidence of NBTE was identified in 19%, a prevalence 10 times higher than that of the control population (Aryana et al., 2006). NBTE vegetations are prone to embolization and can involve multiple organ sites simultaneously. The most common sites of embolization are the cerebrovascular, coronary, splenic, pulmonary, and renal circulations (Aryana et al., 2006).

Cancer therapeutics can also enhance hypercoagulability. Our patient received bevacizumab as part of her adjuvant and maintenance therapy for progressive disease, the patient remained on enoxaparin and did not experience further embolic neurologic complications. The patient died from end-stage OCCC 7 months following her NBTE diagnosis.

### Table 1

| Variable      | Patient values | Normal range |
|---------------|----------------|--------------|
| WBC           | 4.7 × 10^9 cells/μL | 3.9–10.7 × 10^9 cells/μL |
| Hemoglobin    | 7.9 g/dL | 12–16 g/dL |
| Platelets     | 68 × 10^3/μL | 150–450 × 10^3/μL |
| Absolute neutrophil count | 3.52 | 1.5–8.0 (1500 to 8000/mm^3) |
| BUN           | 19 mg/dL | 7–18 mg/dL |
| Creatinine    | 1.0 mg/dL | 0.6–1.2 mg/dL |
| Potassium     | 4.4 mEq/L | 3.5–5.0 mEq/L |
| Sodium        | 138 mEq/L | 135–145 mEq/L |
| Magnesium     | 1.5 mEq/L | 1.5–2.0 mEq/L |
| Calcium       | 8.8 mg/dL | 8.4–10.2 mg/dL |
| PT            | 14.0 s | 11–13 s |
| PTT           | 29.8 s | 25–35 s |
| INR           | 1.14 | 0.8 to 1.2 |
| C-reactive protein | 8.6 mg/dL | <0.5 mg/dL |
| ESR           | 15 mm/h | 0–20 mm/h |
| LDL           | 98 mg/dL | <130 mg/dL |
| Vitamin B12   | 187 pg/mL | 200–800 pg/mL |
| Folate        | 12.4 |  |
| TSH           | 2.33 uU/mL | 0.5–4.6 uU/mL |
| CA125         | 914 U/mL | <35 U/mL |

WBC, white blood cell count; BUN, blood urea nitrogen; PT, prothrombin time; PTT, partial thromboplastin time; INR, international normalized ratio; ESR, erythrocyte sedimentation rate; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.

Variable maps (C, E) consistent with diffusion restriction and acute infarcts. Infarction in the occipital lobe (arrowheads, D) indicate compromise of distal branches of the contralateral posterior cerebral artery. Splenium of the corpus callosum (arrow, D) indicates compromise of the posterior pericallosal artery branch from the posterior cerebral artery, and punctate infarcts in the left occipital lobe (arrowheads, D) indicate compromise of distal branches of the contralateral posterior cerebral artery.
therapy along with anticoagulation therapy. However, after her second debulking she discontinued anticoagulation therapy and received multiple systemic chemotherapy regimens including bevacizumab, which in the absence of anticoagulation therapy may have contributed to hypercoagulability and NBTE. Bevacizumab in particular has been associated with arterial thromboembolism, and to a lesser extent venous thromboembolism, in the setting of malignancy (Nalluri et al., 2008).

Bevacizumab, a recombinant humanized monoclonal antibody that selectively binds to and neutralizes the biologic activity of human VEGF has been shown to increase the risk of arterial thromboembolism when administered with chemotherapy. In a study of 1745 patients with metastatic breast, colorectal, or non-small cell lung carcinoma treated with bevacizumab and chemotherapy versus chemotherapy alone, the chemotherapy plus bevacizumab cohort had a significantly increased risk of developing arterial thromboembolism compared to the chemotherapy-only group (Zacharsi et al., 1983).

Treatment of NBTE consists of both anticoagulation and anti-cancer therapy. Both IV and subcutaneous unfractionated heparin therapy have been found to be effective in reducing the incidence of recurrence of NBTE. Low-molecular-weight heparin may also be used, although there is less evidence for its long-term efficacy (el-Shami et al., 2007). Vitamin K antagonists are less effective in controlling malignancy-associated NBTE (Aryana et al., 2006; el-Shami et al., 2007). The effectiveness of newer anticoagulants such as factor Xa and direct thrombin inhibitors remains to be established. In this patient with prior PE, continuation of anticoagulation therapy could have prevented the development of NBTE.

Adenocarcinoma of the ovary has been described as a cause for NBTE, but OCCC presenting with NBTE is very rare. There are only three published case reports on NBTE in OCCC. Systemic embolization from NBTE to pulmonary, coronary, splenic, and renal territories as presenting sequelae in a patient with stage IIC OCCC have been described (Aryana et al., 2006). However, cerebrovascular infarcts in a patient with clear cell carcinoma with NBTE has only been reported once thus far in a patient with stage IC OCCC who developed sudden onset left homonymous hemianopsia following 6 cycles of adjuvant carboplatin and paclitaxel chemotherapy (Devulapalli et al., 2012).

We report on a patient with advanced OCCC who presented with acute cerebrovascular infarcts secondary to NBTE, a presentation that has not been reported in the literature thus far. We also show that NBTE can be controlled with appropriate anticoagulant therapy even in the face of aggressive metastatic disease and concomitant use of procoagulant anti-cancer therapy. NBTE is a serious and potentially under-diagnosed manifestation of hypercoagulability in OCCC and should be considered in all OCCC patients presenting with multiple embolic events.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal upon request.

References

Aryana, A., Esterbrooks, D., Morris, P., 2006. Nonbacterial thrombotic endocarditis with recurrent embolic events as manifestation of ovarian neoplasm. J. Gen. Intern. Med. 21, 12–15.

Devulapalli, S., Pinto, N., Gandothra, C., Jayam-Trouth, A., Kurukumbi, M., 2012. A rare case of occipital stroke as a consequence of nonbacterial thrombotic endocarditis in ovarian clear cell carcinoma: a case report. Case Rep. Neurol. 4, 84–91.

Dranoff, G., 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11–22.

el-Shami, K., Griffiths, E., Streiff, M., 2007. Nonbacterial thrombotic endocarditis in cancer patients: Pathogenesis, diagnosis, and treatment. Oncologia 12, 518–523.

Goff, B.A., de la Cuesta R. Sainz, HG, Muntz, Fleischhacker, D., M Er, LW, Rice, et al., 1996. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 60, 412–417.

González, Q., Candela, M., Vidal, C., Román, J., Aramburo, P., 1991. Non-bacterial thrombotic endocarditis in cancer patients. Acta Cardiol. 46, 1–9.

Heit, J., Silverstein, M., Morh, D., Pettersson, T., O’Fallon, W., Melton, L.I., 2000. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 160, 809–815.

Lee, A.Y., Levine, M.N., 1999. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin. Thromb. Hemost. 25, 137–145.

Nalluri, S., Chu, D., Keresztes, R., Zhu, X., Wu, S., 2008. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. J. Am. Med. Assoc. 300, 2277–2285.

Nani, H., Hashimoto, H., Kajimoto, E., Takeda, M., Yoshida, S., Miyatake, T., et al., 2013. Cerebral infarctions as manifestation of ovarian clear cell carcinoma: report of two cases and review of the literature. Int. Cancer. Conf. J. 2, 206–210.

Rickles, F., Edwards, R., 1983. Activation of blood coagulation in cancer: Trouseau’s syndrome revisited. Blood 62, 14–31.

Sørensen, H.T., Mellemkjær, L., Olsen, J., Baron, J.A., 2000. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846–1850.

Steiner, J., 1993. Nebakteriální trombotická endokarditida—a studie 171 případu [nonbacterial thrombotic endocarditis—a study of 171 case reports]. Cesk. Patol. 29, 58–60.

Zacharski, L.R., Schned, A.R., Sørensen, G.D., 1983. Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung. Cancer Res. 43, 3963–3968.